By Jason Derry --
Endo to Acquire Indevus
On January 5, 2009, Endo Pharmaceuticals Holdings Inc. announced that it will buy Indevus Pharmaceuticals Inc. for an initial payment of about $370 million and an additional $267 million, based on certain milestones. Currently, Indevus has marketed products for the treatment of overactive bladder, prostate cancer, hypogonadism, and central precocious puberty. Indevus also has a number of potential products in its pipeline. Endo has a number of marketed pain management products. The acquisition will bolster Endo's sales force and product line.
Escalon Acquires Hematology Business
On January 2, 2009, Escalon Medical Corp. announced the acquisition of Immunodiagnostic Systems Holdings' hematology business. According to the press release, the acquisition will cost Escalon $5.9 million spread over the next four years.
Roche Licenses Anti-inflammatory Compounds
On December 30, 2008, BusinessWeek reported that Roche has entered a licensing agreement with Synta Pharmaceuticals for certain preclinical anti-inflammatory compounds. The initial licensing fee is reportedly $25 million in cash. The deal may be worth more than $1 billion in milestones and royalties if three products emerge to market from the licensed compounds.
Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.
Comments